| Study |
Reference |
|
Alsfouk (Topiramate) (Controls exposed to Lamotrigine, sick), 2021
|
Alsfouk, B.A. Antiseizure medications use during pregnancy and congenital malformations: A retrospective study in Saudi Arabia Saudi Pharm. J. 2021; 29:939-.
|
|
Alsfouk (Topiramate) (Controls unexposed, sick), 2021
|
Alsfouk, B.A. Antiseizure medications use during pregnancy and congenital malformations: A retrospective study in Saudi Arabia Saudi Pharm. J. 2021; 29:939-.
|
|
AlSheikh (Topiramate) (Controls exposed to Lamotrigine, sick), 2020
|
AlSheikh Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences (Riyadh) 2020; 25:32-37
|
|
AlSheikh (Topiramate) (Controls unexposed, sick), 2020
|
AlSheikh Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences (Riyadh) 2020; 25:32-37
|
|
Arkilo (Topiramate), 2015
|
Arkilo D Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study. Eur J Paediatr Neurol 2015;19:37-40
|
|
Babic (Topiramate), 2014
|
Babic Postnatal concerns in children born to women with juvenile myoclonic epilepsy. In: European Congress on Epileptology. vol. 55. Stockholm: Epilepsia; 2014: 128
|
|
Bank (Topiramate) (Mixed indications) , 2017
|
Bank Placental passage of antiepileptic drugs at delivery and neonatal outcomes. Epilepsia 2017; 58:e82-e86
|
|
Battino (Topiramate) (Epilepsy), 2024
|
Battino Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy. JAMA Neurol 2024; 81:481-489 Tomson Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018; 17:530-538 Tomson T Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17
|
|
Bech (Topiramate) (Mixed indications), 2018
|
Bech In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry 2018; 89:1324-1331
|
|
Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick), 2018
|
Bjørk Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol 2018; 75:160-168
|
|
Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022
|
Bjork, M. Prenatal antiseizure medication exposure and risk of autism and intellectual disability. SCAN-AED: A Nordic cohort study Eur. J. Neurol. 2021; 28:105-. Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Bjørk (Topiramate) (Controls unexposed NOS) (Mixed indications), 2022
|
Bjork, M. Prenatal antiseizure medication exposure and risk of autism and intellectual disability. SCAN-AED: A Nordic cohort study Eur. J. Neurol. 2021; 28:105-. Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Bjørk (Topiramate) (Controls unexposed, disease free), 2018
|
Bjørk Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol 2018; 75:160-168
|
|
Bjørk (Topiramate) (Controls unexposed, sick), 2018
|
Bjørk Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol 2018; 75:160-168
|
|
Bjørk (Topiramate) (Controls unexposed, sick) (Mixed indications), 2022
|
Bjork, M. Prenatal antiseizure medication exposure and risk of autism and intellectual disability. SCAN-AED: A Nordic cohort study Eur. J. Neurol. 2021; 28:105-. Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Blotière (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019
|
Blotière Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019; 93:e167-e180
|
|
Blotière (Topiramate) (Controls unexposed NOS) (Mixed indications), 2019
|
Blotière Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019; 93:e167-e180
|
|
Bromley (Topiramate), 2016
|
Bromley RL Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology 2016;87:1943-1953
|
|
Christensen (Topiramate) (All indications) (Controls exposed to LTG), 2024
|
Christensen Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur 2024; 38:100849 Dreier Prenatal exposure to antiseizure medication and intrauterine growth restriction in offspring of women with epilepsy Epilepsia 2021; 62(S3):3-364.
|
|
Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024
|
Christensen Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur 2024; 38:100849 Dreier Prenatal exposure to antiseizure medication and intrauterine growth restriction in offspring of women with epilepsy Epilepsia 2021; 62(S3):3-364.
|
|
Cohen (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019
|
Cohen Anticonvulsant Mood Stabilizer and Lithium Use and Risk of Adverse Pregnancy Outcomes. J Clin Psychiatry 2019; 80:
|
|
Cohen (Topiramate) (Controls unexposed NOS) (Mixed indications), 2019
|
Cohen Anticonvulsant Mood Stabilizer and Lithium Use and Risk of Adverse Pregnancy Outcomes. J Clin Psychiatry 2019; 80:
|
|
Cohen (Topiramate) (Mixed indications) (Controls exposed to LTG), 2023
|
Cohen Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations. Ann Neurol 2023; 93:551-562
|
|
Cohen (Topiramate) (Mixed indications) (Controls unexposed, NOS), 2023
|
Cohen Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations. Ann Neurol 2023; 93:551-562
|
|
Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020
|
Blotière Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open 2020; 10:e034829 Coste Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep 2020; 10:17362
|
|
Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020
|
Coste Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep 2020; 10:17362
|
|
Dreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023
|
Dreier Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol 2023; 80:568-577
|
|
Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023
|
Dreier Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol 2023; 80:568-577
|
|
Hao (Topiramate) (Epilepsy) (Controls exposed to LTG), 2025
|
Hao Seizure control and pregnancy outcomes in Chinese women with epilepsy: A prospective multicenter cohort study. Epilepsia 2025; :
|
|
Hao (Topiramate) (Epilepsy) (Controls unexposed, sick), 2025
|
Hao Seizure control and pregnancy outcomes in Chinese women with epilepsy: A prospective multicenter cohort study. Epilepsia 2025; :
|
|
Hernández-Díaz (Topiramate), 2017
|
Hernández-Díaz S Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol 2017;82:457-465
|
|
Hernandez-Diaz (Topiramate) (Epilepsy), 2024
|
Hernandez-Diaz Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure. N Engl J Med 2024; 390:1069-1079
|
|
Hernandez-Diaz (Topiramate) (Mixed indications), 2018
|
Hernandez-Diaz Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. Neurology 2018; 90:e342-e351
|
|
Hernández-Díaz (Topiramate) (Mixed indications), 2012
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9
|
|
Hernández-Díaz (Topiramate) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2014
|
Hernández-Díaz Association between topiramate and zonisamide use during pregnancy and low birth weight.,Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol 2014; 123:21-8 Hernández-Díaz S Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol 2017;82:457-465
|
|
Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014
|
Hernández-Díaz Association between topiramate and zonisamide use during pregnancy and low birth weight.,Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol 2014; 123:21-8 Hernández-Díaz S Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol 2017;82:457-465
|
|
Husebye (Topiramate) (Controls exposed to Lamotrigine, sick), 2020
|
Husebye Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero - the Norwegian Mother and Child Cohort Study. Eur J Neurol 2020; 27:667-675
|
|
Husebye (Topiramate) (Controls unexposed, disease free), 2020
|
Husebye Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero - the Norwegian Mother and Child Cohort Study. Eur J Neurol 2020; 27:667-675
|
|
Husebye (Topiramate) (Controls unexposed, sick), 2020
|
Husebye Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero - the Norwegian Mother and Child Cohort Study. Eur J Neurol 2020; 27:667-675
|
|
Källén (Topiramate) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013
|
Källén B The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6:1221-86 Razaz N Association Between Pregnancy and Perinatal Outcomes Among Women With Epilepsy. JAMA Neurol 2017;74:983-991 Wide K Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004;93:174-6
|
|
Källén (Topiramate) (Controls unexposed, NOS) (Indications NOS), 2013
|
Källén B The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6:1221-86
|
|
Kilic (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Kilic (Topiramate) (Controls unexposed NOS) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Kilic (Topiramate) (Controls unexposed, sick) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Li (Topiramate) (Controls exposed to LTG), 2023
|
He Pregnancy outcome in women with epilepsy in Western China: A prospective hospital based study. Epilepsy Behav 2017; 74:10-14 Li Pregnancy characteristics and adverse outcomes in offspring of women with epilepsy: a prospective registry study from Mainland China. Front Neurol 2023; 14:1195003
|
|
Li (Topiramate) (Controls unexposed, sick), 2023
|
He Pregnancy outcome in women with epilepsy in Western China: A prospective hospital based study. Epilepsy Behav 2017; 74:10-14 Li Pregnancy characteristics and adverse outcomes in offspring of women with epilepsy: a prospective registry study from Mainland China. Front Neurol 2023; 14:1195003
|
|
Lyons (Topiramate) (Indications NOS), 2023
|
Lyons Assessing medical product safety during pregnancy using parameterizable tools in the sentinel distributed database. Pharmacoepidemiol Drug Saf 2023; 32:158-215
|
|
Madley-Dowd_SE (Topiramate) (Controls exposed to LTG) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_SE (Topiramate) (Controls unexposed, general pop) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_SE (Topiramate) (Controls unexposed, sibling) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_UK (Topiramate) (Controls exposed to LTG) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_UK (Topiramate) (Controls unexposed, general pop) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_UK (Topiramate) (Controls unexposed, sibling) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Margulis (Topiramate) (Mixed indication), 2012
|
Margulis Use of topiramate in pregnancy and risk of oral clefts. Am. J. Obstet. Gynecol. 2012; 207:405.e1-7
|
|
Mawer (Topiramate) (Controls exposed to Lamotrigine, sick), 2010
|
Kini Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero.,Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero. Eur J Med Genet ; 50:411-20 Mawer G Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010;19:112-9
|
|
Mawer (Topiramate) (Controls unexposed, disease free), 2010
|
Kini Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero.,Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero. Eur J Med Genet ; 50:411-20 Mawer G Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010;19:112-9
|
|
Mawer (Topiramate) (Controls unexposed, sick), 2010
|
Kini Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero.,Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero. Eur J Med Genet ; 50:411-20 Mawer G Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010;19:112-9
|
|
Meador (Topiramate) (Controls exposed to Lamotrigine, sick), 2021
|
Meador Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study. JAMA Neurol 2021; 78:927-936
|
|
Meador (Topiramate) (Controls exposed to Lamotrigine, sick), 2020
|
Meador Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology 2020; 94:e1502-e1511
|
|
Meador (Topiramate) (Controls unexposed, disease free), 2021
|
Meador Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study. JAMA Neurol 2021; 78:927-936
|
|
Meador (Topiramate) (Controls unexposed, disease free), 2020
|
Meador Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology 2020; 94:e1502-e1511
|
|
Meador (Topiramate) (Controls unexposed, sick), 2020
|
Meador Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology 2020; 94:e1502-e1511
|
|
Mines (Topiramate) (Other indications), 2014
|
Mines Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf 2014; 23:1017-25
|
|
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006
|
Campbell E Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia 2013;54:165-71 Morrow J Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8
|
|
Morrow (Topiramate) (Controls unexposed, sick), 2006
|
Morrow J Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8
|
|
Nadebaum (Topiramate), 2011
|
Nadebaum Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 2011; 76:719-26
|
|
Ornoy (Topiramate), 2008
|
Ornoy The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies.,The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod. Toxicol. 2008; 25:388-9
|
|
Razaz (Topiramate) (Epilepsy), 2024
|
Razaz Risk of Perinatal and Maternal Morbidity and Mortality Among Pregnant Women With Epilepsy. JAMA Neurol 2024; 81:985-995
|
|
Richards (Topiramate) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2019
|
Richards Developmental outcomes at age four following maternal antiepileptic drug use. Epilepsy Behav 2019; 93:73-79
|
|
Richards (Topiramate) (Controls unexposed, NOS) (Indications NOS), 2019
|
Richards Developmental outcomes at age four following maternal antiepileptic drug use. Epilepsy Behav 2019; 93:73-79
|
|
Rihtman (Topiramate) (Mixed indications), 2012
|
Rihtman Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod. Toxicol. 2012; 34:308-11
|
|
The NAAED (Topiramate) (Controls exposed to LTG) (Indications NOS), 2023
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9 Lewis B. Holmes, M.D. (Director) Risk of malformations for specific AED in monotherapy and the control groups (Latest Study Data - October 2023) https://www.aedpregnancyregistry.org/ (Consulted 05/2022) Lewis Holmes Risk of malformations for specific AED in monotherapy and the control groups. Latest Study Data - October 2023. https://www.aedpregnancyregistry.org/ (Consulted September 2024)
|
|
The NAAED (Topiramate) (Controls unexposed, disease free) (Indications NOS), 2023
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9 Lewis B. Holmes, M.D. (Director) Risk of malformations for specific AED in monotherapy and the control groups (Annual Update for 2022) https://www.aedpregnancyregistry.org/ (Consulted 05/2022) Lewis Holmes Risk of malformations for specific AED in monotherapy and the control groups. Latest Study Data - October 2023. https://www.aedpregnancyregistry.org/ (Consulted September 2024) Wyszynski Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64:961-5
|
|
Thomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021
|
Keni Teratogenicity of antiepileptic dual therapy: Dose-dependent, drug-specific, or both? Neurology 2018; 90:e790-e796 Thomas Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia 2017; 58:274-281 Thomas Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP). Seizure 2021; 93:127-132
|
|
Thomas (Topiramate) (Controls unexposed, disease free), 2021
|
Thomas Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia 2017; 58:274-281
|
|
Thomas (Topiramate) (Controls unexposed, sick), 2021
|
Thomas Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia 2017; 58:274-281 Thomas Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP). Seizure 2021; 93:127-132
|
|
Thomas (Topiramate) (Epilepsy) (Controls exposed to LTG), 2022
|
Thomas, S.V. Differential impact of antenatal exposure to antiseizure medications on motor and mental development in infants of women with epilepsy Epileptic Disord. 2022; 24:531-.
|
|
Thomas (Topiramate) (Epilepsy) (Controls unexposed, sick), 2022
|
Thomas, S.V. Differential impact of antenatal exposure to antiseizure medications on motor and mental development in infants of women with epilepsy Epileptic Disord. 2022; 24:531-.
|
|
Tomson (Topiramate), 2018
|
Tomson Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018; 17:530-538 Tomson T Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17
|
|
Trivedi (Topiramate) (Controls exposed to Lamotrigine, sick), 2018
|
Trivedi Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. Epilepsy Res 2018; 146:50-53
|
|
Trivedi (Topiramate) (Controls unexposed, sick), 2018
|
Trivedi Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. Epilepsy Res 2018; 146:50-53
|
|
Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013
|
Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11 Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol. Scand. 2013; 128:228-34
|
|
Vajda (Topiramate) (Controls unexposed, sick), 2013
|
Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand 2013; 128:228-34 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11
|
|
Vajda a (Topiramate) (Controls exposed to LTG) (Epilepsy), 2024
|
Vajda Pregnancy, antiseizure medications and unexplained intrauterine foetal death. Epilepsy Behav 2024; 153:109724 Vajda Anti-epileptic drug exposure and risk of foetal death in utero. Acta Neurol Scand 2018; 137:20-23
|
|
Vajda a (Topiramate) (Controls unexposed sick) (Epilepsy), 2024
|
Vajda Pregnancy, antiseizure medications and unexplained intrauterine foetal death. Epilepsy Behav 2024; 153:109724 Vajda Anti-epileptic drug exposure and risk of foetal death in utero. Acta Neurol Scand 2018; 137:20-23
|
|
Vajda b (Topiramate) (Epilepsy) (Controls exposed to Lamotrigine, sick), 2024
|
Vajda Teratogenicity of the newer antiepileptic drugs--the Australian experience. J Clin Neurosci 2012; 19:57-9 Vajda Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure 2010; 19:558-61 Vajda The prescribing of antiepileptic drugs for pregnant Australian women. Aust N Z J Obstet Gynaecol 2012; 52:49-53 Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand 2013; 128:228-34 Vajda The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51:805-10 Vajda The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007; 47:468-74 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11 Vajda The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014; 130:234-8 Vajda The teratogenesis risk associated with antiseizure medication duotherapy in women with epilepsy. Epilepsy Res 2024; 200:107316
|
|
Vajda b (Topiramate) (Epilepsy) (Controls unexposed, sick), 2024
|
Vajda Teratogenicity of the newer antiepileptic drugs--the Australian experience. J Clin Neurosci 2012; 19:57-9 Vajda Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure 2010; 19:558-61 Vajda The prescribing of antiepileptic drugs for pregnant Australian women. Aust N Z J Obstet Gynaecol 2012; 52:49-53 Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand 2013; 128:228-34 Vajda The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51:805-10 Vajda The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007; 47:468-74 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11 Vajda The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014; 130:234-8 Vajda The teratogenesis risk associated with antiseizure medication duotherapy in women with epilepsy. Epilepsy Res 2024; 200:107316
|
|
Veiby (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Veiby (Topiramate) (Controls unexposed, disease free) (Mixed indications), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Veiby (Topiramate) (Controls unexposed, sick) (Mixed indications), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Wood (Topiramate), 2015
|
Wood Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy. Epilepsia 2015; 56:1047-55
|
